

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

## Test

Sample	Group		N	Result	N <sub>rel</sub>
<b>(461) anti-cardiolipin screening</b>					
A	(2) EIA (ELISA)	>>>	15	Negative	94 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	1	Negative	6,3 %
	Total per sample: n = 16	Success: 100 %			
B	(2) EIA (ELISA)	>>>	15	Positive	94 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	1	Positive	6,3 %
	Total per sample: n = 16	Success: 100 %			
Total success: 100 %					
<b>(463) anti-cardiolipin IgG</b>					
A	(2) EIA (ELISA)	>>>	43	Negative	72 %
	(3) FIA (FEIA, TRACE)	>>>	2	Negative	3,3 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	14	Negative	23 %
	(99) Another measurement principle	>>>	1	Negative	1,7 %
	Total per sample: n = 60	Success: 100 %			
B	(2) EIA (ELISA)		1	Negative	1,7 %
		>>>	42	Positive	70 %
	(3) FIA (FEIA, TRACE)	>>>	2	Positive	3,3 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	14	Positive	23 %
	(99) Another measurement principle	>>>	1	Positive	1,7 %
	Total per sample: n = 60	Success: 98 %			
Total success: 98 %					
<b>(464) anti-cardiolipin IgM</b>					
A	(2) EIA (ELISA)	>>>	42	Negative	71 %
	(3) FIA (FEIA, TRACE)	>>>	2	Negative	3,4 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	14	Negative	24 %
	(99) Another measurement principle	>>>	1	Negative	1,7 %
	Total per sample: n = 59	Success: 100 %			
B	(2) EIA (ELISA)	>>>	42	Negative	71 %
	(3) FIA (FEIA, TRACE)	>>>	2	Negative	3,4 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	14	Negative	24 %
	(99) Another measurement principle	>>>	1	Negative	1,7 %
	Total per sample: n = 59	Success: 100 %			
Total success: 100 %					
<b>(465) anti-beta2-GP 1 screening</b>					
A	(2) EIA (ELISA)	>>>	13	Negative	93 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	1	Negative	7,1 %
	Total per sample: n = 14	Success: 100 %			
B	(2) EIA (ELISA)		1	Negative	7,1 %
			1	Inconclusive result (borderline)	7,1 %
		>>>	11	Positive	79 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	1	Positive	7,1 %
	Total per sample: n = 14	Success: 86 %			
Total success: 86 %					
<b>(467) anti-beta2-GP 1 IgG</b>					
A	(2) EIA (ELISA)	>>>	38	Negative	69 %
	(3) FIA (FEIA, TRACE)	>>>	2	Negative	3,6 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	14	Negative	25 %
	(99) Another measurement principle	>>>	1	Negative	1,8 %
	Total per sample: n = 55	Success: 100 %			
B	(2) EIA (ELISA)		7	Negative	13 %
		>>>	31	Positive	56 %
	(3) FIA (FEIA, TRACE)	>>>	2	Positive	3,6 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	14	Positive	25 %
	(99) Another measurement principle	>>>	1	Positive	1,8 %
	Total per sample: n = 55	Success: 87 %			
Total success: 87 %					
<b>(468) anti-beta2-GP 1 IgM</b>					
A	(2) EIA (ELISA)	>>>	37	Negative	69 %
	(3) FIA (FEIA, TRACE)	>>>	2	Negative	3,7 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	14	Negative	26 %
	(99) Another measurement principle	>>>	1	Negative	1,9 %
	Total per sample: n = 54	Success: 100 %			
B	(2) EIA (ELISA)	>>>	37	Negative	69 %

## Summary statistics - qualitative results

(Groups: measurement principle)

## EQA round: APLA2/21 - Antiphospholipid Antibodies

Deadline: 01.10.2021

Test					
Sample	Group		N	Result	N <sub>rel</sub>
B	(3) FIA (FEIA, TRACE)	>>>	2	Negative	3,7 %
	(4) LIA (CLIA, CMIA, ECLIA, LOCI)	>>>	14	Negative	26 %
	(99) Another measurement principle	>>>	1	Negative	1,9 %
Total per sample: n = 54			Success: 100 %		
Total success: 100 %					

st\_kl End of report

Printed: 06.10.2021